Replies to post #18311 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

The short answer: M281 and (especially) M254 appear to have more commercial potential than anyone (including MNTA) previously thought. For investors, this has offset the demise of the Copaxone program as a material profit engine and the stretched-out target date for product revenue from the FoB programs.

[floblu14]

....something is helping to support the current price. Is it the hope for sale of assets or acquisition?

Among several topics discussed - let's add this one from MNTA's recent patent estate -

METHODS FOR THE TREATMENT OF NEURODEGENERATION 2017-06-09

[Neurodegeneration is the progressive loss of structure or function of neurons, including death of neurons. Many neurodegenerative diseases including amyotrophic lateral sclerosis, Parkinson's, Alzheimer's, and Huntington's occur as a result of neurodegenerative processes.]

https://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=1&ND=3&adjacent=true&locale=en_EP&FT=D&date=20170609&CC=HK&NR=1221681A1&KC=A1

Abstract: The invention encompasses the discovery that Fc-containing polypeptides that include branched glycans and that are sialylated on the branched glycan (e.g., on an a 1,3 and/or a 1,6 arm in the Fc region's N-linked glycosylation site), with, e.g., a NeuAc-a 2,6-Gal or NeuAc-a 2,3-Gal terminal linkage, are useful in treating neurodegeneration, e.g., in the treatment of neurodegenerative diseases such as Alzheimer's Disease.

http://www.freshpatents.com/-dt20160331ptan20160090409.php